Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Best International Stock: Novo Nordisk

Discover an entire world of compelling investing opportunities in our "Best International Stocks" series.

I can't think of anything better in an international stock than finding a company that's the leader in its field, markets its products to the whole planet, and is unaffected by recessions. There aren't many companies like this in the world, but Danish drugmaker Novo Nordisk (NYSE: NVO  ) is one of them.

Never heard of Novo Nordisk? That's OK. If you know someone with either type of diabetes, then there's a good chance they're using one of Novo's drugs. Novo Nordisk is the worldwide leader in treating diabetes, which is a disease whose prevalence is unfortunately growing at an amazing rate. The World Health Organization estimates that eight years ago, 171 million people had either type 1 or type 2 diabetes. Today, more than 200 million people have it, and by 2030, this figure will jump to 366 million people worldwide. Needless to say, this presents a huge growth opportunity for diabetes care drugmakers.

Novo Nordisk's insulin and other diabetes drugs are used in the whole range of diabetes treatment regimens for insulin-dependent type 1 diabetes patients to early-stage adult-onset type 2 diabetes, often caused by a sedentary lifestyle and obesity. Novo Nordisk does have tough competitors like Sanofi-Aventis (NYSE: SNY  ) , Eli Lilly (NYSE: LLY  ) , and Merck (NYSE: MRK  ) , but Novo has a stronger and broader diabetes drug product portfolio than these competitors.

In the past couple of years, there have been several innovative diabetes treatments to enter the market, like Merck's Januvia, Amylin Pharmaceuticals' (Nasdaq: AMLN  ) Byetta, and new ones still in the works like MannKind's (Nasdaq: MNKD  ) inhaled insulin Technosphere. One thing that none of these drugs fully replaces, though, are Novo Nordisk's rapid-acting insulin analogues and long-lasting insulins.

Even better, Novo is also working on developing compounds in some of these new classes of diabetes therapies like GLP-1 analogues and will benefit from the evolution in diabetes care. Novo isn't just focused on treating diabetes. It markets other drugs, like uncontrolled bleeding treatment NovoSeven, has a modest biopharmaceuticals pipeline, and is also testing some of its diabetes treatments in new indications like obesity.

Novo's shares can be bought as an American depositary receipt (ADR) on the New York Stock Exchange, so there's no hassle in dealing with foreign stock exchanges. Even better, since Novo is located in Denmark, investors get to benefit from any weakening of the dollar as the price of the ADR adjusts upward to account for these currency moves.

In Novo's just-announced year-end financials, sales were up 13% in 2007, net income spiked 32% upward, and earnings were $2.46 per share. 2008 guidance is for operating profit growth of 25%. Trading at 25 times forward analyst earnings guidance and 26 times its just-released trailing earnings, Novo won't show up on any value investor's stock screens, but it's hard to complain because Novo is operating in a recession-proof sector.

What makes Novo Nordisk exciting is its long-term Rule Breakers-type of growth potential. More and more people around the world will be using Novo's products in the years to come. For those investors wanting to own shares of an international drugmaker at the epicenter in fighting a huge health crisis, Novo Nordisk fits the bill.

Read/Post Comments (0) | Recommend This Article (10)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 569375, ~/Articles/ArticleHandler.aspx, 10/24/2016 9:03:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 0.00%
S&P 500 2,141.16 -0.18 0.00%
NASD 5,257.40 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:02 PM
NVO $41.50 Down +0.00 +0.00%
Novo Nordisk CAPS Rating: *****
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
LLY $78.25 Down +0.00 +0.00%
Eli Lilly and Co. CAPS Rating: ***
MNKD $0.59 Down +0.00 +0.00%
MannKind CAPS Rating: *
MRK $61.20 Down +0.00 +0.00%
Merck and Co. CAPS Rating: ****
SNY $37.75 Down +0.00 +0.00%
Sanofi CAPS Rating: *****